genuine question about biopsy that I am slightly embarrassed to ask
dual agonist. That is the whole post, but I will justify it. Everything else people worry about in c/meta is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort dual agonist out first, and almost nobody does. I say this having got it wrong for 18 months. My…
Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.
Strongly agree. The safety story is separate.
MASH claims need the trial and the biopsy endpoint
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1